NCT07296341

HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors

A Phase IB/II Study To Evaluate the Safety, Tolerability, and Preliminary Efficacy of HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a randomized, open-label, multicenter Phase II clinical trial designed to evaluate the Safety, Tolerability and Preliminary Efficacy of HRS-4642 Combination with Other Antitumor Therapies in Patients with Solid Tumors

Conditions

• Locally Advanced or Metastatic Pancreatic Cancer With

Interventions

Type	Name	Description
DRUG	HRS-4642;Adebrelimab Injection; nab-paclitaxel; gemcitabine	HRS-4642 combination with Adebrelimab Injection, nab-paclitaxel in combination with gemcitabine
DRUG	HRS-4642;nab-paclitaxel; gemcitabine	nab-paclitaxel in combination with gemcitabine

Timeline

• Start date: 2026-01-08
• Primary completion: 2027-10-01
• Completion: 2027-12-01
• First posted: 2025-12-22
• Last updated: 2026-01-14

Locations

1 site across 1 country: China